Research Progress in Bleeding Risk Assessment of Non-Vitamin K Antagonist Oral Anticoagulant in Atrial Fibrillation.
10.3881/j.issn.1000-503X.16331
- Author:
Chao YU
1
;
Wei ZHOU
1
;
Tao WANG
1
;
Ling-Juan ZHU
1
;
Hui-Hui BAO
1
;
Xiao-Shu CHENG
1
Author Information
1. Center for Prevention and Treatment of Cardiovascular Diseases, The Second Affiliated Hospital of Nanchang University,Nanchang 330006,China.
- Publication Type:Review
- Keywords:
atrial fibrillation;
bleeding risk;
gene;
non-vitamin K antagonist oral anticoagulant
- MeSH:
Humans;
Atrial Fibrillation/drug therapy*;
Anticoagulants/therapeutic use*;
Hemorrhage/chemically induced*;
Risk Assessment;
Administration, Oral;
Risk Factors
- From:
Acta Academiae Medicinae Sinicae
2025;47(3):452-461
- CountryChina
- Language:English
-
Abstract:
The introduction of non-vitamin K antagonist oral anticoagulant (NOAC) into clinical use heralds a new age for anticoagulation therapy in patients with atrial fibrillation (AF).However,anticoagulation-related bleeding is currently a major challenge in the anticoagulation process.Assessing the risk of anticoagulation-related bleeding is an important part for the management of patients with AF.Clinical risk factor scores have moderate ability to predict the risk of anticoagulation-related bleeding.To improve the anticoagulation safety of NOACs,additional clinical and biological markers and genetic polymorphisms should be considered to enhance the predictive capability for anticoagulation-related bleeding.This review summarizes the challenges in the management of anticoagulation therapy,with emphases on the bleeding risk scores,biomarkers,clinical indicators,and genetic loci currently used to guide the risk assessment of anticoagulation-related bleeding in AF patients.This review is expected to provide research insights and reference frameworks for predicting and evaluating the bleeding risk associated with NOACs.
